| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| References | |
|---|---|
| Additional Infomation |
Clonixin is a pyridine monocarboxylic acid, a compound in which nicotinic acid is substituted at the 2-position with a (2-methyl-3-chlorophenyl)amino group. It (in the form of a lysine salt) is used to treat renal colic, muscle pain, and moderate migraine attacks. It has a variety of pharmacological effects, including nonsteroidal anti-inflammatory drug (NSAID), nonnarcotic analgesic, antipyretic, platelet aggregation inhibitor, vasodilator, EC 1.14.99.1 (prostaglandin intraperoxidase) inhibitor, and lipoxygenase inhibitor. It is a pyridine monocarboxylic acid, an aminopyridine compound, and an organochlorine compound whose function is related to nicotinic acid. It is the conjugate acid of Clonixin (1-). Clonixin is a nonsteroidal anti-inflammatory drug. It is an anti-inflammatory analgesic. Drug Indications It is indicated for the treatment of chronic arthritis and certain soft tissue disorders associated with pain and inflammation. Mechanism of Action The mechanism of action of Clonixin appears not to have been studied at the molecular level. It is speculated that its mechanism of action is similar to other nonsteroidal anti-inflammatory drugs (NSAIDs), reducing prostaglandin production by inhibiting cyclooxygenases 1 and 2.
Pharmacodynamics Clonicoxin is a nonsteroidal anti-inflammatory drug (NSAID) with a structure similar to [DB00586]. It has vasodilatory and analgesic effects. |
| Molecular Formula |
C13H11CLN2O2
|
|---|---|
| Molecular Weight |
262.69
|
| Exact Mass |
262.05
|
| CAS # |
17737-65-4
|
| PubChem CID |
28718
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
410.2±45.0 °C at 760 mmHg
|
| Melting Point |
242 °C
|
| Flash Point |
201.9±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.665
|
| LogP |
5.09
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CLOMYZFHNHFSIQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H11ClN2O2/c1-8-10(14)5-2-6-11(8)16-12-9(13(17)18)4-3-7-15-12/h2-7H,1H3,(H,15,16)(H,17,18)
|
| Chemical Name |
2-(3-chloro-2-methylanilino)pyridine-3-carboxylic acid
|
| Synonyms |
Deltar; lysine clonixinate; Clonixin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~380.68 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8068 mL | 19.0338 mL | 38.0677 mL | |
| 5 mM | 0.7614 mL | 3.8068 mL | 7.6135 mL | |
| 10 mM | 0.3807 mL | 1.9034 mL | 3.8068 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
